BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned
Aug 14 (Reuters) - Amarin Corporation Plc
* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee
* Amarin Corporation says ‍independent data monitoring committee recommended that trial continue as planned without modification​
* Says ‍results from completed study are expected in Q2 or Q3 2018​
* Says ‍anticipates that onset of approximately 100 pct of events will likely occur in early 2018​
* Amarin Corp - ‍interim efficacy analysis performed after adjudication of about 80 pct of target 1,612 aggregate primary cardiovascular events occurred within study​ Source text for Eikon: Further company coverage: